fencingforum.com

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    The Collapse of Genesis Capital May Change Crypto Lending – Instead of Burying It

    January 28, 2023

    Samson Rock Capital LLP invests $1.62 million in DXC Technology (NYSE:DXC)

    January 28, 2023

    Layer 1 Crypto Project Explodes 190% in Just One Week Amid Rollout of New Revenue Features

    January 28, 2023
    Facebook Twitter Instagram
    fencingforum.com
    • Home
    • News

      Why are Tesla fires so hard to put out?

      January 27, 2023

      Thanks to OpenAI, Microsoft beats Google in the artificial intelligence game

      January 26, 2023

      Facebook lifts ban on former President Donald Trump

      January 25, 2023

      DOJ sues Google again for antitrust violations over its ads

      January 24, 2023

      Jeff Bezos says he’s giving away his wealth to charity. What does that mean?

      January 24, 2023
    • Crypto

      The Collapse of Genesis Capital May Change Crypto Lending – Instead of Burying It

      January 28, 2023

      Layer 1 Crypto Project Explodes 190% in Just One Week Amid Rollout of New Revenue Features

      January 28, 2023

      Federal Reserve Offers Devastating ‘Surprise’ Bitcoin And Crypto Blow After Huge Price Surge

      January 28, 2023

      IRS Reminds Taxpayers to Report Crypto Income Ahead of 2022 Filings

      January 28, 2023

      3 Busy Crypto Presales to Invest in 2023 Could Soar 100x! Big Eyes Coin, Dododoge, Calvaria

      January 28, 2023
    • Startup

      Jitendra Singh urges young people to take advantage of startup opportunities

      January 28, 2023

      Jitendra Singh urges young people to take advantage of startup opportunities

      January 28, 2023

      Bits and Bytes: Learn about Pune Startups, Business News

      January 28, 2023

      Startup Mantra: Picking the Best Agricultural Mechanization Products

      January 28, 2023

      Piyush Goyal calls for a stronger global startup ecosystem

      January 28, 2023
    • Technology

      Samson Rock Capital LLP invests $1.62 million in DXC Technology (NYSE:DXC)

      January 28, 2023

      Carpenter Technology’s (NYSE:CRS) price target was raised to $54.00 by Cowen

      January 28, 2023

      Glenmede Trust Co. NA purchases shares in Microchip Technology Incorporated (NASDAQ:MCHP)

      January 28, 2023

      Metaverse and Immersive Technologies Survey 2022-2023: Results for IT Business Makers

      January 28, 2023

      6 surprising new developments in travel insurance that will change the way you plan your next trip

      January 28, 2023
    • Trending

      Here’s why Bigg Boss 16: Shame On Farah Khan is trending on Twitter.

      January 28, 2023

      Shiitake nigiri, tofu and banyaki: green is the trend!

      January 28, 2023

      Ballistic Software — Hot and Trending in 2023

      January 28, 2023

      I like Guillemot’s (EPA:GUI) return. The trends are:

      January 28, 2023

      COVID, flu and RSV cases are trending downward across the United States. What about Virginia?

      January 28, 2023
    Facebook Twitter Instagram
    fencingforum.com
    Home»Startup»Pharmaceutical manufacturing has one major flaw. This synthetic biology startup has raised $200 million for him to fix it.
    Startup

    Pharmaceutical manufacturing has one major flaw. This synthetic biology startup has raised $200 million for him to fix it.

    admin1By admin1January 5, 20234 Mins Read
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Asimov’s four co-founders (left to right): Doug Densmore, Alec Nielsen, Raja Srinivas, … [+] Chris Voight.

    Asimov.

    A room in the shadow of Boston’s infamous Fenway Park Stadium is illuminated by a giant, dynamically changing fluorescent globe.

    Here’s a video of the cell, nature’s infinite nanofactory, churning out millions of molecules every second.

    On the screen in front of me, I see a biological circuit reformatted by software, reminiscent of a Red Sox home run base loop. The basic building blocks of life are laid out in stages, predicting the performance of cellular components as if you were modeling a rocket ship.

    “All cells are capable of computation. Perceiving environmental signals, processing information, turning genes on and off,” My host, Alec Nielsen, says he’s CEO and co-founder of Asimov, a company that builds tools for designing living systems.

    “I believe that the ability to engineer this evolutionary gift will be the most significant and impactful technology humans have ever developed.”

    This is a vision shared by investors and over 25 customers, including the top 10 pharmaceutical and biotech companies. That’s why Asimov this week raised $200 million worth of new funding to expand his drug discovery toolkit.

    Funding includes $175 million Series B led by Canada Pension Plan Investments (CPP Investments) with participation from Fidelity Investments, KDT, Casdin Capital, Pillar and Andreessen Horowitz (a16z) doing.

    Drug discovery bottleneck

    Asimov is a spin-out of Chris Voigt’s lab at MIT, co-founded by Nielsen and Voigt, Raja Srinivas, and Doug Densmore from Boston University.

    Explaining what inspired him to join Voigt’s lab as a PhD student, Nielsen said: “How can we get this field closer to the engineering field, without brute force trial and error?”

    Accelerating the discovery of cell-derived therapeutics is an important philosophy.

    Nielsen quotes Scott Gottlieb, former Commissioner of the U.S. Food and Drug Administration. “For regular drugs, 80% of his complexity is in clinical trials. With cell and gene therapy, it’s the other way around. His 80% of complexity is in manufacturing,” he said. I’m here.

    The manufacturing process is a major bottleneck, especially when using mammalian cells. Even after a lengthy discovery process reveals new therapeutics, it is difficult to generate antibodies or RNA in sufficient quantity and purity.

    “Cures that used to be science fiction are now reaching patients.”

    Nielsen says. “But the technology to design and manufacture these medicines has not caught up. A trial-and-error approach does not scale.”

    Better design tools for biology

    Nielsen draws an eloquent analogy between genetic engineering today and computer science in the 1970s. Next, an image of an Intel engineer hand-carving a stencil of a semiconductor circuit. He now has a supercomputer packed with 10 million transistors.

    So Asimov is applying engineering principles to bring biology to life. They also have an excellent toolkit that combines gene-edited mammalian cell lines with a computer-aided design platform they call kernels.

    It’s a clever name for its biological origins through corn, but it’s also a term for the layer between a computer’s hardware and operating system.

    A kernel starts with a database of known biological parts. Elements of the DNA code. These parts can then be combined into circuits, just as you would in an electronic circuit. The software predicts how they will work together to produce therapeutic proteins such as antibodies.

    “This is in some ways the ultimate goal of computational synthetic biology,” says Nielsen. “Being able to predict genetic systems on a computer”

    Improving drug development

    Asimov not only provides customers with specialized cell lines that can be customized with these biological moieties, but also provides access to the software and instructions on how to use it.

    Let’s say you’re trying to improve antibody production. Maybe make more of it or remove impurities. Kernels can be used to fine-tune genetic circuits and experimentally test optimal combinations.

    Asimov is currently focused on two major commercial applications. One uses CRISPR-engineered Chinese hamster cells and their accompanying genetic templates to improve the production of proteins such as antibodies. It is famous for being developed in response.

    “In the future, we plan to expand to other domains,” says Nielsen. “But now we want to do mammalian synthetic biology therapeutics and be the best. It’s a bed, it’s a beachhead market.”

    It’s an exciting prospect. As your toolkit grows, so do the possibilities.

    “Our database now contains thousands of gene segments,” says Nielsen. “But one day we will reach billions. We hope this will become a truly comprehensive repository of every gene function needed for every biotech application. ”

    thank you very much peter bickerton For additional research and reporting on this article. I am the founder of his SynBioBeta and operating partner of his DCVC that invested in Asimov. SynBioBeta Conference When weekly digest.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    admin1
    • Website

    Related Posts

    Startup January 28, 2023

    Jitendra Singh urges young people to take advantage of startup opportunities

    Startup January 28, 2023

    Jitendra Singh urges young people to take advantage of startup opportunities

    Startup January 28, 2023

    Bits and Bytes: Learn about Pune Startups, Business News

    Startup January 28, 2023

    Startup Mantra: Picking the Best Agricultural Mechanization Products

    Startup January 28, 2023

    Piyush Goyal calls for a stronger global startup ecosystem

    Startup January 28, 2023

    Piyush Goyal calls for a stronger global startup ecosystem

    Leave A Reply Cancel Reply

    Recent Comments

    No comments to show.

    Archives

    • January 2023
    • December 2022
    • November 2022
    • October 2022
    • September 2022
    • March 2022
    • February 2022
    • December 2021

    Categories

    • Crypto
    • Make money
    • News
    • Startup
    • Technology
    • Trending
    • Uncategorized
    Facebook Twitter Instagram Pinterest
    • Home
    • Contact us
    • DMCA
    • Privacy Policy
    • Sitemap
    © 2023 opzionebinaria. Designed by opzionebinaria.

    Type above and press Enter to search. Press Esc to cancel.